ArticleMedicine2025
Oblique lumbar interbody fusion combined with anterolateral screw fixation for treating severe lumbar spinal stenosis: Case series.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is controversial for indirect decompression like oblique lumbar interbody fusion (OLIF) for treating severe lumbar spinal stenosis (SLSS). OLIF combined with anterolateral screw fixation (AF) can achieve decompression and fixation by single incision, which is minimally invasive. In this study, we aimed to evaluate the effectiveness and safety of OLIF-AF for treating SLSS. A retrospective study which comprised patients diagnosed with L4-5 SLSS of Schizas grade C or D caused by degenerative conditions who underwent L4-5 OLIF-AF with a follow-up of 24 months. Preoperative Visual Analog Scale score of low-back pain and leg pain, and Oswestry Disability Index, disc height, foraminal area, ligamentum flavum thickness, difference of left and right facet angle, and cross-sectional area (CSA) were compared to their 1 day, 3 months, 12 months, and 24 months postoperative counterparts. Eighty-two patients of L4-5 SLSS underwent OLIF-AF were included in this retrospective study. Ligamentum flavum thickness thinned from 4.94 ± 1.20 mm to 4.20 ± 0.95 mm after the operation, and 3.91 ± 0.78 mm and 3.87 ± 0.75 mm (all P < .05) at 12 and 24 months postoperatively. CSA expanded from 52.44 ± 15.38 mm2 to 103.98 ± 20.44 mm2 on postoperative day 1, and expand to 115.77 ± 20.04 mm2 and 117.71 ± 20.83 mm2 (all P < .05) at each annual follow-up. Visual Analog Scale score of low-back pain improved from 6.40 ± 0.99 to 2.56 ± 0.85 at 3 months postoperatively, then reached 1.55 ± 0.69 and 1.12 ± 0.64 (all P < .05) at each annual follow-up. Visual Analog Scale score of leg pain gradually improved from 6.16 ± 1.25 to 2.37 ± 0.82, 1.36 ± 0.71, and 1.10 ± 0.69 (all P < .05) at each time point. Oswestry Disability Index increased from 37.54 ± 6.01 to 18.81 ± 4.38 (P < .05) after surgery. And recovered to 12.42 ± 2.44 (P < .05) and 10.58 ± 1.63 (P < .05) at 1 and 2 years postoperatively. OLIF-AF can effectively restore disc height, foraminal area, and CSA, reducing lumbar rotation, thinning the hypertrophic ligamentum flavum, significantly improving patients' pain and function, and maintaining efficacy, indicating that OLIF-AF may be a safe and effective treatment for SLSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.